Search for other papers by Pepijn van Houten in
Google Scholar
PubMed
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
Search for other papers by James Nagarajah in
Google Scholar
PubMed
Search for other papers by Janneke E W Walraven in
Google Scholar
PubMed
Search for other papers by Martin Jaeger in
Google Scholar
PubMed
Search for other papers by Adriana C H van Engen-van Grunsven in
Google Scholar
PubMed
Search for other papers by Johannes W Smit in
Google Scholar
PubMed
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
Search for other papers by Romana T Netea-Maier in
Google Scholar
PubMed
and resistance to RAI-induced apoptosis ( 8 ). Strategies for restoring thyroid-specific gene expression by so-called ‘redifferentiation’, and thus NIS and TPO expression and function, followed by the administration of RAI, are promising treatment
Search for other papers by Abdul Rehman Syed in
Google Scholar
PubMed
Search for other papers by Aakash Gorana in
Google Scholar
PubMed
Search for other papers by Erik Nohr in
Google Scholar
PubMed
Search for other papers by Xiaoli-Kat Yuan in
Google Scholar
PubMed
Search for other papers by Parthiv Amin MASc in
Google Scholar
PubMed
Search for other papers by Sana Ghaznavi in
Google Scholar
PubMed
Search for other papers by Debbie Lamb in
Google Scholar
PubMed
Search for other papers by John McIntyre in
Google Scholar
PubMed
Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
://doi.org/10.1056/NEJMoa1209288 ) 7 Rothenberg SM McFadden DG Palmer EL Daniels GH & Wirth LJ . Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib . Clinical Cancer Research 2015 21 1028
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Search for other papers by Junyu Tong in
Google Scholar
PubMed
Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
Search for other papers by Maomei Ruan in
Google Scholar
PubMed
Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Search for other papers by Hao Fu in
Google Scholar
PubMed
Search for other papers by Lin Cheng in
Google Scholar
PubMed
Search for other papers by Qiong Luo in
Google Scholar
PubMed
Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Search for other papers by Zhiyan Liu in
Google Scholar
PubMed
Search for other papers by Zhongwei Lv in
Google Scholar
PubMed
Search for other papers by Libo Chen in
Google Scholar
PubMed
Vivian G Harmer C . A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer . Clinical Oncology 2004 16 569 – 574 . ( https://doi.org/10.1016/j.clon.2004.06.018 ) 81 Kebebew E Lindsay
Search for other papers by Andries H Groen in
Google Scholar
PubMed
Search for other papers by Deborah van Dijk in
Google Scholar
PubMed
Search for other papers by Wim Sluiter in
Google Scholar
PubMed
Search for other papers by Thera P Links in
Google Scholar
PubMed
Search for other papers by Hendrik P Bijl in
Google Scholar
PubMed
Search for other papers by John T M Plukker in
Google Scholar
PubMed
.1210/jc.2007-2357 ) 8 Liu J Liu Y Lin Y Liang J . Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy . Endocrinology and Metabolism 2019 34 215 – 225 . ( https://doi.org/10.3803/EnM.2019.34.3.215 ) 9
Search for other papers by Carles Zafon in
Google Scholar
PubMed
Department of Medicine, University of Alcalá de Henares, Madrid
Search for other papers by Juan J. Díez in
Google Scholar
PubMed
IdiSNA (Instituto de investigación en la salud de Navarra), Pamplona, Spain
Search for other papers by Juan C. Galofré in
Google Scholar
PubMed
Search for other papers by David S. Cooper in
Google Scholar
PubMed
emerging therapeutic targets. Lancet Diabetes Endocrinol 2014;2:830-842. 52 Wong K-P, Lang BH-H: New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review. J
Search for other papers by Andrew G Gianoukakis in
Google Scholar
PubMed
Search for other papers by Jennifer H Choe in
Google Scholar
PubMed
Search for other papers by Daniel W Bowles in
Google Scholar
PubMed
Search for other papers by Marcia S Brose in
Google Scholar
PubMed
Search for other papers by Lori J Wirth in
Google Scholar
PubMed
Search for other papers by Taofeek Owonikoko in
Google Scholar
PubMed
Search for other papers by Svetlana Babajanyan in
Google Scholar
PubMed
Search for other papers by Francis P Worden in
Google Scholar
PubMed
Aashiq M Silverman DA Na’ara S Takahashi H & Amit M . Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies . Cancers 2019 11 . ( https://doi.org/10.3390/cancers11091382 ) 9
Search for other papers by Furio Pacini in
Google Scholar
PubMed
Search for other papers by Dagmar Fuhrer in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Daria Handkiewicz-Junak in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Johannes W Smit in
Google Scholar
PubMed
with higher prevalence in these tumors than in classical PTC. As already mentioned, many tumors with aggressive histology, do not express NIS and do not have RAI uptake. This is the basis for redifferentiation protocols and such patients should be
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Dagmar Fuhrer in
Google Scholar
PubMed
Search for other papers by Barbara Jarzab in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Jan Smit in
Google Scholar
PubMed
, dermatology, and cardiology. Several novel and promising perspectives are available for the treatment of advanced TC. Ongoing studies are evaluating the efficacy and safety of new MKIs, redifferentiation therapies, and of immunotherapeutic compounds to be
Search for other papers by Chantal A Lebbink in
Google Scholar
PubMed
Search for other papers by Thera P Links in
Google Scholar
PubMed
Search for other papers by Agnieszka Czarniecka in
Google Scholar
PubMed
Search for other papers by Renuka P Dias in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Louise Izatt in
Google Scholar
PubMed
Search for other papers by Heiko Krude in
Google Scholar
PubMed
Search for other papers by Kerstin Lorenz in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Arnoldo Piccardo in
Google Scholar
PubMed
Search for other papers by Manuel Sobrinho-Simões in
Google Scholar
PubMed
Search for other papers by Toru Takano in
Google Scholar
PubMed
Search for other papers by A S Paul van Trotsenburg in
Google Scholar
PubMed
Search for other papers by Frederik A Verburg in
Google Scholar
PubMed
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
461 – 470 ( https://doi.org/10.1089/thy.2018.0597 ) 122 Aashiq M Silverman DA Na’ara S Takahashi H Amit M . Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies . Cancers